Alzamend Neuro, Inc.
ALZN
$2.22
-$0.14-5.93%
NASDAQ
| 07/31/2025 | 04/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 39.27% | 16.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 137.09% | 9.78% | |||
| Operating Income | -137.09% | -9.78% | |||
| Income Before Tax | -137.20% | -9.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -137.20% | -9.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -137.20% | -9.62% | |||
| EBIT | -137.09% | -9.78% | |||
| EBITDA | -137.28% | -9.92% | |||
| EPS Basic | 47.23% | -43.44% | |||
| Normalized Basic EPS | 19.89% | 5.51% | |||
| EPS Diluted | 47.23% | -43.44% | |||
| Normalized Diluted EPS | 19.89% | 5.51% | |||
| Average Basic Shares Outstanding | 196.08% | 16.02% | |||
| Average Diluted Shares Outstanding | 196.08% | 16.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||